Cantor Fitzgerald Forecasts DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of ($0.62) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($2.58) per share.

Bright Minds Biosciences (NASDAQ:DRUG) last released its quarterly earnings results on Monday, December 30th. The company reported ($0.12) earnings per share for the quarter.

Other research analysts also recently issued research reports about the stock. Robert W. Baird initiated coverage on shares of Bright Minds Biosciences in a report on Monday, November 25th. They issued an “outperform” rating and a $75.00 target price on the stock. Piper Sandler started coverage on shares of Bright Minds Biosciences in a report on Thursday. They issued an “overweight” rating and a $93.00 target price on the stock. Baird R W upgraded shares of Bright Minds Biosciences to a “strong-buy” rating in a research report on Monday, November 25th. Finally, HC Wainwright started coverage on shares of Bright Minds Biosciences in a research report on Friday, January 10th. They issued a “buy” rating and a $85.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Bright Minds Biosciences has an average rating of “Buy” and a consensus price target of $84.33.

Bright Minds Biosciences Stock Performance

Shares of DRUG opened at $33.35 on Thursday. The company has a market capitalization of $147.74 million, a PE ratio of -66.70 and a beta of -6.52. Bright Minds Biosciences has a one year low of $0.93 and a one year high of $79.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.31 and a quick ratio of 11.31. The company’s fifty day moving average price is $38.57 and its 200 day moving average price is $21.00.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.